NDAINJECTIONINJECTABLEPriority Review
Approved
Dec 1985
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
3/8 — Basic
Priority Review
INDIUM IN 111 OXYQUINOLINE (indium in-111 oxyquinoline) by GE HealthCare is radiopharmaceutical activity [moa]. Approved for radioactive diagnostic agent [epc]. First approved in 1985.
Drug data last refreshed 19h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Indium In-111 Oxyquinoline is a radioactive diagnostic agent used for nuclear imaging to visualize and assess organ and tissue function. It is injected intravenously and binds to white blood cells or other target tissues to enable detection of infection, inflammation, or organ dysfunction. The radiopharmaceutical delivers diagnostic data through gamma camera imaging rather than providing therapeutic benefit.
LOE Approaching
As a legacy radiopharmaceutical approaching loss of exclusivity, the brand team is likely small and focused on managed decline rather than growth initiatives.
Mechanism of Action
Radiopharmaceutical Activity
Pharmacologic Class:
Radioactive Diagnostic Agent
Indications (1)
Career Relevance
Working on Indium In-111 Oxyquinoline offers limited career growth due to its LOE-approaching status and zero linked job openings; roles are focused on product maintenance, compliance, and managed decline. This is a legacy product assignment best suited for early-career professionals seeking diagnostic expertise or those in transition roles, not a springboard for advancement.
Worked on INDIUM IN 111 OXYQUINOLINE at GE HealthCare? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.